Solventum Corporation SOLV
This picture changes. Follow Solventum Corporation free — email when the signal or risk changes + a Sunday weekly brief.
Follow Solventum Corporation freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 7 Aug 2026
Latest news check: 7 Jun 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Existing position can be maintained pending the Q3 report.
Strong organic growth and the HIS separation plan outweigh high execution risk and temporary cash-flow effects.
Market sentiment
7/10
↑
Trend: Improving
The market reacts positively to the unexpected HIS spin-off announcement and the strong Q2 report.
Price context
The stock trades near its 52-week high after a 19.2 percent rise over the past three months, indicating that much of the positive news is already priced in.
Risk assessment
6/10
Dilution:
Low
Active buyback program and positive cash flow
Jurisdiction:
Low
Operations primarily in US and developed markets
Execution:
High
Complex separation from 3M and planned HIS spin-off
About the company
Solventum is a standalone healthcare company spun off from 3M in 2024. Operations include MedSurg products, Dental Solutions and Health Information Systems with focus on medical technology and software.
Sector:
Healthcare and medtech
Type:
Producer
Next report
15 Nov 2026
Q3
Catalysts
Nov 2026
HIS separation
High
Q3 2027
Q3 report
High
Horizon:
Bull case
Strong organic growth and raised guidance after the Q2 report support momentum ahead of the HIS separation.
Bear case
Negative cash flows early in the year and temporary ERP effects may weigh on Q3 results.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Organic sales growth | If organic growth falls below 2 percent, momentum for guidance upgrades disappears. | If organic growth exceeds 4 percent, confidence in margin expansion and separation increases. |
| HIS separation execution | Delayed or costly separation increases debt burden and delays focus. | Successful separation unlocks value and enables faster debt reduction. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Strong organic growth and the HIS separation plan outweigh high execution risk and temporary cash-flow effects.
Recent news
- The Q2 report on 5 August 2026 showed 9.5 percent organic growth and raised full-year guidance. The company simultaneously announced its intention to separate Health Information Systems within 12–18 months.
Key figures
Revenue
Q2 2026
USD 2.2B
Revenue TTM
TTM
USD 8,281M
EBITDA
FY 2025
USD 2,549M
Net income
Q2 2026
USD 92.0M
Cash
Q2 2026
USD 561M
Total debt
Q2 2026
USD 5.3B
Gross margin
Q3 2025
55.5%
Shares outstanding
Q2 2026
172M
EPS
Q2 2026
USD 0.54
Price & valuation
Last close
USD 85.21
Market Cap
USD 14.6B
1 week
-2.6 %
3 months
+14.5 %
12 months
+18.2 %
From 52w high
-3.8 %
From 52w low
+36.4 %
Exchange
NYSE
Type
Producer
Sector
Healthcare and medtech
This picture changes. Follow Solventum Corporation free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.